Sami Labs Limited

Sami-sabinsa Group Limited

Majeed, Muhammed

Sivakumar Arumugam

Kalyanam Nagabhushanam

Muhammed Majeed

Furqan Ali

Shaheen Majeed

Kirankumar Beede

Lakshmi Mundkur

Natarajan Sankaran

Muthuraman Gnanamani

Anju Majeed

Priti Vaidyanathan

Suresh Karri

Anurag Pande

Ugraiah Amilineni

Kulithalai Viswanathan Krishnamurthy

Jamsheeda Moothedath

John Adams Sebastian

Samuel Thomas Manoharan

Krishnamurthy Kulithalai Viswanathan

Nooruddin Thajuddin

The present invention discloses a novel fructophilic lactic acid producing bacteriastrain FF-7 (MTCC 25235) and the process of isolation and characterization of the bacteria.

Fructophilic lactic acid producing bacteria

The present invention discloses a method of isolating secondary metabolites, specifically arjunolic acid, from the calli and/or the suspension cultures derived from the pluripotent cambium tissue of. The invention also discloses a method of inducing callus, establishing and maintaining suspension cultures of callus derived from the cambium offor the isolation of secondary metabolites.

Method of isolating secondary metabolites from cambium derived callus cultures

Disclosed are the skin care applications of a composition containing the partially purified extracellular metabolite isolated fromMTCC 5856. More specifically, the invention discloses the ability of the partially purified extracellular metabolite isolated fromMTCC 5856 to confer protection to the skin fibroblasts against UV induced cell damage and apoptosis, oxidative stress and inflammation.

Skin care applications of extracellular metabolites from Bacillus coagulans

The present invention discloses the potential of probiotic bacteriaindividually or in combination with multi-enzyme complex for reducing gluten content in foods rich in gluten and for the increased utilization of gluten. The invention further discloses a method for the management of gluten intolerance using composition comprisingand multi-enzyme complex in mammals.

Method and composition for therapeutic management of gluten intolerance

A probiotic-alcoholic beverage composition comprisingis disclosed herein wherein the said spore or vegetative cell ofexhibited high recovery, tolerability, compatibility and viability of spores and vegetative cells after brewing. Methods for brewing an alcoholic beverage composition comprisingwherein said spore or bacterium is added during pre-fermentation, during fermentation and post fermentation stages are also disclosed.

Alcoholic beverage composition containing

The present invention discloses a novel endophytic fungi,MTCC 25236 for the bioconversion of curcuminoids to Calebin-A and a method for its isolation from the rhizomes ofsp. The invention also discloses a method for the bioconversion of curcuminoids to Calebin-A using an endophytic fungiMTCC 25236 and bacterial species,and

Microbial bioconversion of curcuminoids to calebin-A

The present invention discloses a composition comprising heat inactivated spores and/or comprising heat inactivated vegetative cells of probiotic bacteria, and a process for preparing the same. The invention also discloses a method of modulating immune function in mammals by activating macrophages, using a composition comprisingin the form of live or heat inactivated spore and/or vegetative cells.

Modulation of immune function by

Disclosed is the hypolipidemic potential of. More specifically the invention discloses the cholesterol lowering potential ofMTCC 5856 and therapeutic/biological indications thereof.

Hypolipidemic effects of

The present invention discloses a stable probiotic composition comprisingindividually and/or in combination with multi-enzyme complex for the utilization of lactose and therapeutic management of lactose intolerance. It also discloses a method for the management of lactose intolerance using composition comprisingindividually and/or in combination with multi-enzyme complex.

Stable probiotic composition for the management of lactose intolerance

The present invention discloses a novel fructophilic lactic acid producing bacteriastrain FF-7 (MTCC 25235) and the process of isolation and characterization of the bacteria. The invention also discloses the biological applications/therapeutic use of fructophilic lactic acid producing bacteria in increased utilization of fructose from food stuff and in the managing disorders related to high fructose intake.

The present invention discloses beverage compositions comprising probioticand water soluble prebiotic fibers that have been subjected to treatments under extreme stress, temperature and pressure conditions like brewing or aeration wherein the spore viability is maintained post said treatments.

Beverage compositions containingMTCC 5856

Disclosed are hair care compositions containing partially purified extracellular metabolite preparation from strains of. Specifically, the uses of compositions containing extracellular metabolite preparation from a strain offor increasing hair growth, inhibition of 5&#x3b1;-reductase and proliferation of follicle dermal papilla cells and in the management of androgenic alopecia, are disclosed.

Hair care compositions containing extracellular metabolite preparation from

Disclosed is the use of partially purified extracellular metabolite isolated fromMTCC 5856 to prevent skin aging. More specifically the invention discloses the anti-collagenase, anti-elastase, anti-glycation activity and enhancement of TGF-&#x3b2;, epidermal growth factor and hyaluronic acid expression in human dermal fibroblasts, of extracellular metabolites isolated fromMTCC 5856.

Anti-aging potential of extracellular metabolite isolated fromMTCC 5856

Disclosed are the methods and compositions for the reduction of intestinal gas/flatulence. Specifically a method for reducing flatulence using a composition containing probiotic bacteriaMTCC 5856 is disclosed. More specifically, the invention discloses a method for inhibiting the growth of microorganisms that facilitate the production of intestinal gas, using a composition containing probiotic bacteriaMTCC 5856.

Compositions and methods for reducing flatulence

Disclosed are compositions containing at least 10% w/w or above of 1-O-galloyl-&#x3b2;-D-glucose (&#x3b2;-glucogallin) which additionally comprising of about 10% w/w to greater than 60% w/w total mucic acid gallates including mucic acid 1,4-lactone 5-O-gallate, mucic acid 2-O-gallate, mucic acid 6-Methyl ester 2-O-gallate, mucic acid 1-Methyl ester 2-O-gallate and ellagic acid, and a probiotic bacteriaMTCC 5856, individually or in combination for inhibiting the growth and managing infections of

Growing community of inventors

Bengaluru, India

Sivakumar Arumugam